Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
Last trade$18.29
Day change-$0.18 (-0.97%)
Day range$18.19 – $19.10
Volume233,474
Market cap$901M
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$901.15M
Price / earnings
—
Price / book
2.02×
Price / sales
1.87×
EV / sales
2.55×
EV / EBITDA
40.56×
Profitability
Earnings per share
-$0.36
Return on assets
-1.69%
Return on equity
-3.94%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.84×
Current ratio
4.42×
Quick ratio
3.02×
Cash ratio
0.63×
Cash flow
Price / cash flow
60.51×
Price / free cash flow
—
Free cash flow
-$44.38M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AORT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$123.79M
$125.76M
$116.34M
$115.99M
$113.39M
$112.97M
$98.98M
$97.31M
Cost of revenue
$47.81M
$45.24M
$40.89M
$42.85M
$38.99M
$39.86M
$35.4M
$35.81M
Gross profit
$75.98M
$80.52M
$75.45M
$73.14M
$74.4M
$73.11M
$63.58M
$61.5M
Selling, general and administrative
$63.22M
$79.83M
$60.82M
$56.84M
$57.28M
$57.67M
$54.7M
$51.43M
Research and development
$9.81M
$9.06M
$8.84M
$9.12M
$8.08M
$7.06M
$6.73M
$7.4M
Total operating expenses
$73.03M
$88.88M
$69.66M
$69.46M
$65.36M
$64.73M
$61.43M
$58.83M
Operating income
$2.95M
-$8.36M
$5.79M
$3.68M
$9.04M
$8.38M
$2.15M
$2.67M
Interest expense
-$8.52M
-$7.25M
-$5.37M
-$5.53M
-$6.12M
-$7.27M
-$7.66M
-$9.74M
Income before taxes
-$5.92M
-$11.7M
$339K
$6.54M
$7.06M
$3.48M
-$2.3M
-$16.6M
Income taxes
$2.01M
$1.81M
-$1.08M
$4.11M
$554K
$2.14M
-$1.79M
-$119K
Net income
-$7.93M
-$13.51M
$1.42M
$2.43M
$6.5M
$1.35M
-$505K
-$16.48M
Net income attributable to common shareholders
-$7.93M
-$13.51M
$1.42M
$2.43M
$6.5M
$1.35M
-$505K
-$16.48M
EBITDA
$10.29M
-$1.62M
$12.13M
$9.44M
$14.75M
$13.92M
$7.59M
$8.96M
Basic earnings per share
-$0.16
-$0.28
$0.03
$0.05
$0.14
$0.03
-$0.01
-$0.39
Diluted earnings per share
-$0.16
-$0.28
$0.03
$0.05
$0.13
$0.03
-$0.01
-$0.47
Recent news
Company coverage with links to the original publishers.
The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.
Artivion reported Q3 2026 earnings of $0.08 per share, missing the consensus estimate of $0.11 and down from $0.16 year-ago. The company beat revenue expectations at $123.79 million, up from $113.39 million year-over-year. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market. The Medical-Instruments industry ranks in the top 43% of Zacks industries. Peer company Orthofix is expected to report results on November 9 with anticipated earnings of $0.11 per share, down 45% year-over-year.
OrthoPediatrics (KIDS) reported a quarterly loss of $0.23 per share, beating the consensus estimate of $0.25 loss, with an 8% earnings surprise. Revenue of $72.66 million also exceeded expectations by 6.01%. The stock has gained 35.3% year-to-date, outperforming the S&P 500's 12.1% gain. However, the company maintains a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market.
Yarger Wealth Strategies made a contrarian bet by acquiring 634,223 shares of Artivion (AORT), making it the fund's largest holding at 9.35% of assets under management. The $25.02 million investment comes as Artivion shares have declined 21.4% over the past year, underperforming the S&P 500 by 46.6 percentage points. The medtech company specializes in cardiac and vascular surgical products.
Artivion Inc, a cardiac and vascular solutions company, has received mixed analyst ratings with an average 12-month price target of $43.83. The company shows strong financial performance with impressive revenue growth, net margin, and efficient asset utilization.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.